Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Source-reported fields
Filing overview
- Type
- Registration
- Posted
- Jun 24, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Client
- NOVARTIS
- Filing UUID
- aac65482-7d93-4b1d-ac81-afa24c2a552a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.